Wiener Privatklinik
| Turkey | Austria | Spain | |
| Stem cell therapy for ALS (amyotrophic lateral sclerosis) | from $30,000 | from $60,000 | from $40,000 |
| Stem Cell Therapy | from $7,200 | from $8,500 | from $8,500 |
| Plasmapheresis | from $1,200 | from $2,000 | from $1,800 |
Dr. Fritz Leutmezer is a senior neurologist at Vienna General Hospital, one of Europe's largest university hospitals.
Dr. Fritz Leutmezer is a neurologist at Wiener Privatklinik in Vienna. He specializes in multiple sclerosis, epilepsy, and neurodegenerative diseases. Dr. Leutmezer holds an Associate Professorship at the Medical University of Vienna. He significantly helped shape modern European and Austrian MS treatment guidelines.
Dr. Josef Grohs is a prominent orthopedic surgeon at Vienna General Hospital (AKH). He serves as the Chair of AO-Spine Austria. This doctor specializes in complex spine surgery and manual medicine. He has managed orthopedic cases in Europe and Africa. Dr. Grohs treats conditions like scoliosis, ankylosing spondylitis, and hip fractures.
Dr. Klaus Novak is a neurosurgeon at Döbling Private Hospital in Vienna. He introduced intraoperative motor evoked potential monitoring to Austria. This technique improves patient safety during complex nerve surgeries. Dr. Novak specializes in spine surgery and brain tumor treatment. He completed clinical research at Beth Israel Hospital in the United States.
Stem-cell therapy for ALS is available in Austria primarily through strict clinical trials. While permitted under European Union regulations, it is not a standard medical treatment. Private clinics in Vienna offer autologous protocols using a patient's own bone marrow or fat tissue under specific safety guidelines.
Bookimed Expert Insight: Data shows a clear distinction between academic centers and private facilities in Vienna. While large institutions like Vienna General Hospital (AKH) lead research, private hospitals like Wiener Privatklinik offer more personalized diagnostic access. Patients should confirm that any proposed stem-cell protocol is registered with the European Medicines Agency (EMA) to ensure it meets national ethics requirements for ALS care.
Patient Consensus: Patients note that while consultations are easy to book, stem-cell therapy is rarely offered as a standard option outside of research. Many suggest verifying clinical trial status before traveling to Austria for these specific regenerative treatments.
Austrian multidisciplinary ALS care integrates neurology, pulmonology, and nutritional support within centralized university clinics and private facilities. Leading centers like Vienna General Hospital (AKH) coordinate specialized teams. These clinics provide rapid diagnostics, genetic testing, and individualized symptom management through a single-visit approach for complex neurodegenerative care.
Bookimed Expert Insight: Patients can access elite expertise at Wiener Privatklinik, where over 400 physicians include many professors from the Medical University of Vienna. This provides private-sector comfort with the clinical depth of a major academic institution. This combination is ideal for patients seeking rapid diagnostic timelines without sacrificing specialized university-level insights.
Patient Consensus: Patients note that while integrated care for respiratory and nutritional needs is excellent, initiating early physiotherapy often requires persistence. Coordinating quarterly full-team assessments in major cities like Vienna or Innsbruck is recommended to catch swallowing issues early.
Medical tourists can typically schedule remote neurological evaluations in Austria within 1 to 2 weeks. In-person diagnostic assessments in Vienna generally occur within 48 to 72 hours of arrival. Treatment for ALS often begins 4 to 12 weeks after the initial inquiry.
Bookimed Expert Insight: While Vienna General Hospital (AKH) serves over 595,000 patients annually, private facilities like Wiener Privatklinik offer faster access to professors from the Medical University of Vienna. Securing a slot at a private hospital can reduce the administrative wait for rare neurological consultations by several weeks compared to public university tracks.
Patient Consensus: Patients report that preparing medical records in German or English significantly speeds up the process. Many note that while initial evaluations are quick, starting specialized treatments often requires a 2-month window for insurance and ethics clearance.
Intrathecal stem-cell infusion for ALS is generally safe and well-tolerated. Most documented risks are mild and temporary. Serious adverse events remain rare. These complications often stem from the lumbar puncture procedure rather than the cells. Most symptoms resolve within days with standard medical care.
Bookimed Expert Insight: Clinical data from major Austrian centers like Vienna General Hospital (AKH) shows that safety is linked to institutional volume. Large university hospitals manage over 500,000 patients annually. They follow strict ISO standards that reduce procedural risks. In contrast, small private clinics may lack these rigorous safety benchmarks. Patients should choose facilities with 20+ specialized departments to ensure emergency neurological support is available if needed.
Patient Consensus: Patients emphasize distinguishing between expected post-procedure fevers and acute deterioration. Many note that choosing accredited facilities is vital to avoid spinal infection risks during the infusion.
Patients should plan to stay in Austria for 7 to 14 days for ALS stem-cell therapy. This timeframe includes initial neurological evaluations and specialized laboratory cell processing. It also covers the procedure itself and 72 hours of mandatory post-treatment observation before flying.
Bookimed Expert Insight: Major Austrian centers like Vienna General Hospital manage over 500,000 patients annually. Their protocols for complex neurological cases prioritize stability over speed. We see that a 14-day stay significantly improves immediate recovery compared to 5-day trips. Choosing an academic hospital ensures access to multidisciplinary teams if respiratory support is needed.
Patient Consensus: Patients note that ALS-related fatigue can double recovery time compared to other treatments. It is important to arrange caregiver assistance for the flight home and throughout the stay.
Austrian clinics provide Edaravone IV to non-EU patients through named patient importation schemes. Access is available at specialized centers in Vienna for international cash-pay patients. Physicians legally prescribe these infusions for patients lacking alternative treatments. Administration typically occurs in high-standard private or university hospitals.
Bookimed Expert Insight: While Vienna General Hospital (AKH) serves nearly 600,000 patients yearly, its many professors also practice at Wiener Privatklinik. This allows international patients to access the same top-tier university expertise within a more flexible private environment. Private facilities often manage the complex paperwork for importing non-EMA approved drugs faster than large public institutions.
Patient Consensus: Patients note that private clinics in Austria accept non-EU citizens for Edaravone cycles if they pay out-of-pocket. Many emphasize the need to secure a medical visa early due to the long duration of repeating infusion schedules.
Coverage for ALS treatment in Austria depends on residency status and insurance type. Statutory health insurance (ÖGK) covers comprehensive care for residents. EU visitors use the EHIC for standard care. Private international plans often cover medication and therapy. Experimental treatments like stem cell therapy usually require out-of-pocket payment.
Bookimed Expert Insight: While Vienna General Hospital (AKH) serves over 595,000 patients yearly, residential paperwork takes one to six months. Private clinics like Wiener Privatklinik provide faster access to professors from the Medical University of Vienna. These private facilities often specialize in complex diagnostics for international patients not covered by the public system.
Patient Consensus: Patients note that public insurance covers home adaptations and medication for residents. However, non-residents often pay €200 for specialist visits and must budget extra for home care.
Austria's primary centres for Amyotrophic Lateral Sclerosis (ALS) treatment are in Vienna. Specialised clinics include the Vienna General Hospital (AKH) and Wiener Privatklinik. These facilities offer multidisciplinary care and diagnostic tools. They also provide access to international clinical research protocols for managing motor neuron diseases.
Bookimed Expert Insight: Vienna General Hospital (AKH) is a major public complex with 1,600 doctors. Private hospitals like Wiener Privatklinik offer faster access to specialists. Many professors from the university hospital also practise at these private clinics. This allows patients to receive university-level expertise in a boutique, multilingual environment.
Austria structures ALS care through centralised university clinics using a single-visit outpatient model. Teams coordinate neurologists, respiratory specialists, and therapists in one location. This framework means patients receive comprehensive evaluations every 3 months. This helps to manage rapid disease progression effectively.
Bookimed Expert Insight: University centres like Vienna General Hospital (AKH) handle 595,000 patients yearly. Private facilities like Döbling Private Hospital specialise in servicing Commonwealth patients. Australians should note that these private clinics often apply JCI safety standards for international cases. This helps bridge the gap between public research and personalised, multilingual support for families.
Patient Consensus: Patients emphasise that early coordination between speech therapy, mobility aids, and home nursing is vital. Success depends on clear family instructions and a dedicated coordinator. This helps to prevent delays in equipment delivery or nutritional support in Austria.
Austria provides disease-modifying treatments for ALS including Riluzole and the gene-targeted therapy Tofersen (Qalsody). These medications, authorised by the European Medicines Agency (EMA), aim to slow disease progression. Austrian university hospitals and specialist private centres manage these therapies.
Bookimed Expert Insight: Patients in Austria benefit from a highly integrated academic medical system. Leading centres like Vienna General Hospital (AKH) serve over 595,000 patients annually. Neurologists like Dr Fritz Leutmezer are active in national medical societies. This means patients often gain earlier access to hospital-specific programs for gene therapies.
Patient Consensus: Patients note that Riluzole is the standard first step. Access to newer infusions in Austria often requires management within a specialist neuromuscular clinic.
Patients in Austria can access international clinical trials for Amyotrophic Lateral Sclerosis (ALS) through major research hubs. The Medical University of Vienna collaborates with TRICALS, a European network for ALS research. These partnerships bring phase 2 and phase 3 medication trials to local academic centres.
Bookimed Expert Insight: The link between private hospitals and academic institutions in Vienna is a major advantage. Clinics like Wiener Privatklinik share staff with the Medical University of Vienna. This gives patients access to specialists who also lead clinical trials. Researching doctors with university affiliations can bridge the gap between private care and research.
Patient Consensus: Enrolment depends on meeting strict criteria like disease stage and respiratory function. Patients find that having their own neurologist contact trial sites directly improves their chances.
Stem cell therapy for ALS is available in Austria. This happens primarily through clinical trials and approved experimental protocols. Facilities such as Wiener Privatklinik and Vienna General Hospital (AKH) provide these treatments. All procedures must follow strict European Union safety standards for medicinal products.
Bookimed Expert Insight: Many countries offer experimental care. However, Austria stands out because its university-linked clinics employ over 1,600 doctors. Vienna General Hospital (AKH) is one such facility. This means patients often receive care from professors who publish research on neurodegenerative disorders. For ALS, specialised treatment can range from A$82,800 to A$138,000. These prices reflect the intensive medical monitoring required for these complex protocols.
Patient Consensus: Patients note that Austrian treatment is distinctly experimental. It requires a confirmed diagnosis from a neurologist. Experience shows that coordinating logistics with specialists like Dr Fritz Leutmezer helps manage expectations regarding outcomes in Vienna. Patients also find it helpful to verify study protocols beforehand.